40
Participants
Start Date
August 21, 2023
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2027
Niraparib
Niraparib (Zejula) will be administered as an oral treatment once daily (continuously in a 28-day cycle). Niraparib will be administered in a dose escalation design where patients will start at a dose of 100 mg PO daily for the first two cycles (28-days each cycle), if tolerated, the dose will be increased to 200 mg PO daily for the third and fourth cycle.
RECRUITING
Sunnybrook Research Institute, Toronto
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Sunnybrook Health Sciences Centre
OTHER